Syquant Capital SAS’s Aimmune Therapeutics AIMT Stock Holding History

Syquant Capital SAS’s Portfolio AIMT Stock Details AIMT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q4	–	Sell	-125,547	Closed	-$4.33M	–	112
2020 Q3	$4.33M	Buy	+125,547	New	+$2.67M	2.2%	12

Syquant Capital SAS's AIMT Position: Q4 2020 in Review

Syquant Capital SAS sold out of Aimmune Therapeutics (AIMT) in Q4 2020, closing a stake of 125,547 shares — an estimated $4.33M sold.

Syquant Capital SAS first reported a position in AIMT in Q3 2020 and held it in 1 quarter. The position peaked at $4.33M in Q3 2020. 0 funds tracked by Wall St. Rank hold AIMT as of Q4 2020.

Syquant Capital SAS reported no remaining Aimmune Therapeutics position as of Q4 2020 after selling out during the quarter.
Syquant Capital SAS sold 125,547 Aimmune Therapeutics shares in Q4 2020, an estimated $4.33M.
Syquant Capital SAS first reported a position in Aimmune Therapeutics in Q3 2020 and held it in 1 quarter.
Syquant Capital SAS's Aimmune Therapeutics position peaked at $4.33M in Q3 2020.
0 funds tracked by Wall St. Rank held Aimmune Therapeutics as of Q4 2020.

Based on Syquant Capital SAS's 13F filing for Q4 2020, filed 5 Feb 2021.